CoChat

Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1

Open access
Xu, Heng, Zhao, Hongfang, Ding, Chunyong, Jiang, Defang, Zhao, Zijie, Li, Yang, Ding, Xiaoyu, Gao, Jing, Zhou, Hu, Luo, Cheng, Chen, Guoqiang, Zhang, Ao, Xu, Ying, Zhang, Hao · 2023 · Signal Transduction and Targeted Therapy
Cited by 183

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

As a terpenoids natural product isolated from the plant Thunder God Vine, Celastrol is widely studied for its pharmacological activities, including anti-tumor activities. The clinical application of Celastrol is strictly limited due to its severe side effects, whereas previously revealed targets and mechanism of Celastrol seldom reduce its in vivo toxicity via structural optimization. Target identification has a far-reaching influence on the development of innovative drugs, and omics data has been widely used for unbiased target prediction. However, it is difficult to enrich target of specific phenotype from thousands of genes or proteins, especially for natural products with broad promising activities. Here, we developed a text-mining-based web-server tool to enrich targets from omics data of inquired compounds. Then peroxiredoxin 1 (PRDX1) was identified as the ROS-manipulating target protein of Celastrol in colorectal cancer. Our solved high-resolution crystal structure revealed the unique covalent binding mode of Celastrol with PRDX1. New derivative compound 19-048 with improved potency against PRDX1 and selectivity towards PRDX2~PRDX6 were synthesized based on crystal structure analysis. Both Celastrol and 19-048 effectively suppressed the proliferation of colorectal cancer cells. The anti-tumor efficacy of Celastrol and 19-048 was significantly diminished on xenograft nude mice bearing PRDX1 knock-down colorectal cancer cells. Several downstream genes of p53 signaling pathway were dramatically up-regulated with Celastrol or 19-048 treatment. Our findings reveal that the side effects of Celastrol could be reduced via structural modification, and PRDX1 inhibition is promising for the treatment of colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-022-01231-4

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Metadata

Authors
Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., Ding, X., Gao, J., Zhou, H., Luo, C., Chen, G., Zhang, A., Xu, Y., & Zhang, H.
Venue
Signal Transduction and Targeted Therapy
Published
2023-02-03
Volume
8
Issue
1
Pages
51-51
ISSN
2059-3635 (ISSN-L)
OpenAlex
W4318943172
Cited by
183
References
15
FWCI
45.77
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. https://app.cochat.ai/papers/10.1038/s41392-022-01231-4
The paper
Xu, H., Zhao, H., Ding, C., Jiang, D., Zhao, Z., Li, Y., Ding, X., Gao, J., Zhou, H., Luo, C., Chen, G., Zhang, A., Xu, Y., & Zhang, H. (2023). Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-022-01231-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.